← Leaderboards
Michael Edwin Boulton
University Of Alabama At Birmingham
$9,864,814
Attributed
$18,140,773
Total exposure
10
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.3M · FY2007–25$2.5M$1.9M$1.3M$625K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$18,140,773 · 10
By mechanism
R01$17,747,054 · 9
R21$393,719 · 1
Top collaborators
- Maria B Grant31 shared
- Julia V Busik4 shared
- Qiuhong Li4 shared
- Mervin C. Yoder4 shared
- Charles J Frazier3 shared
- Michael A King1 shared
Most similar at University Of Alabama At Birmingham
Same institution · by research overlap
- Maria B Grant$24,532,308
- Charles J Frazier$5,884,504
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsMouse ModelRetinalRetinaBaseDiabetic RetinopathyFunctional DisorderProteinsDiabetes MellitusPathologyDiabeticTissuesPhenotypeMediatingEndothelial CellsBone MarrowMicrovascular DysfunctionPathogenesisPreventRepairedIn VitroRegulationAreaIn Vivo
Grant awards (47)
ACE2 on gut barrier dysfunction and BRB disruption$369,431
R01 · FY2025 · EY
ACE2 on gut barrier dysfunction and BRB disruption$369,431
R01 · FY2024 · EY
ACE2 on gut barrier dysfunction and BRB disruption$369,431
R01 · FY2023 · EY
ACE2 on gut barrier dysfunction and BRB disruption$369,431
R01 · FY2022 · EY
Human IPSC for Repair of Vasodegenerative Vessels in Diabetic Retinopathy$535,787
R01 · FY2021 · EY
ACE2 Modulates the Bone Marrow- Gut Axis in Diabetic Retinopathy$391,180
R01 · FY2021 · EY
A critical role for intracellular VEGF receptor translocation in ocular angiogenesis$360,112
R01 · FY2021 · EY · contact PI
Human IPSC for Repair of Vasodegenerative Vessels in Diabetic Retinopathy$554,358
R01 · FY2020 · EY
Somatostatin blockade of CNS autonomic hyperactivity for treatment of diabetic retinopathy$461,792
R01 · FY2020 · EY
ACE2 Modulates the Bone Marrow- Gut Axis in Diabetic Retinopathy$403,279
R01 · FY2020 · EY
A critical role for intracellular VEGF receptor translocation in ocular angiogenesis$371,250
R01 · FY2020 · EY · contact PI
Human IPSC for Repair of Vasodegenerative Vessels in Diabetic Retinopathy$552,358
R01 · FY2019 · EY
Somatostatin blockade of CNS autonomic hyperactivity for treatment of diabetic retinopathy$471,105
R01 · FY2019 · EY
ACE2 Modulates the Bone Marrow- Gut Axis in Diabetic Retinopathy$403,279
R01 · FY2019 · EY
A critical role for intracellular VEGF receptor translocation in ocular angiogenesis$371,250
R01 · FY2019 · EY · contact PI
Human IPSC for Repair of Vasodegenerative Vessels in Diabetic Retinopathy$552,358
R01 · FY2018 · EY
LXR as a Novel Therapeutic Target in Diabetic Retinopathy$522,331
R01 · FY2018 · EY
Somatostatin blockade of CNS autonomic hyperactivity for treatment of diabetic retinopathy$474,726
R01 · FY2018 · EY
ACE2 Modulates the Bone Marrow- Gut Axis in Diabetic Retinopathy$415,404
R01 · FY2018 · EY
A critical role for intracellular VEGF receptor translocation in ocular angiogenesis$371,250
R01 · FY2018 · EY · contact PI
LXR as a Novel Therapeutic Target in Diabetic Retinopathy$555,127
R01 · FY2017 · EY
OPTIMIZING SYSTEMIC STEM/PROGENITOR CELL THERAPY FOR AMD$546,187
R01 · FY2017 · EY · contact PI
Somatostatin blockade of CNS autonomic hyperactivity for treatment of diabetic retinopathy$501,851
R01 · FY2017 · EY
Human iPSC for repair of vasodegenerative vessels in diabetic retinopathy$445,991
R01 · FY2017 · EY
Human IPSC for Repair of Vasodegenerative Vessels in Diabetic Retinopathy$125,000
R01 · FY2017 · EY
LXR as a novel therapeutic target in diabetic retinopathy$532,879
R01 · FY2016 · EY
Optimizing systemic stem/progenitor cell therapy for AMD$489,698
R01 · FY2016 · EY · contact PI
LXR as a novel therapeutic target in diabetic retinopathy$582,429
R01 · FY2015 · EY
Optimizing systemic stem/progenitor cell therapy for AMD$515,942
R01 · FY2015 · EY · contact PI
Optimizing systemic stem/progenitor cell therapy for AMD$513,987
R01 · FY2014 · EY · contact PI
Optimizing systemic stem/progenitor cell therapy for AMD$589,587
R01 · FY2013 · EY · contact PI
Circadian-dependent autophagy in retinal maintenance and diabetes$126,113
R21 · FY2013 · EY · contact PI
Circadian-dependent autophagy in retinal maintenance and diabetes$47,856
R21 · FY2013 · EY · contact PI
Autophagy: A critical factor in RPE aging and AMD$319,323
R01 · FY2012 · EY · contact PI
Circadian-dependent autophagy in retinal maintenance and diabetes$219,750
R21 · FY2012 · EY · contact PI
Non-canonical VEGF receptor signaling regulates retinal neovascularization$211,434
R01 · FY2012 · EY · contact PI
Non-canonical VEGF receptor signaling regulates retinal neovascularization$161,066
R01 · FY2012 · EY · contact PI
Autophagy: A critical factor in RPE aging and AMD$26,662
R01 · FY2012 · EY · contact PI
Autophagy: A critical factor in RPE aging and AMD$345,985
R01 · FY2011 · EY · contact PI
Targeting gamma-secretase activation for anti-angiogenesis$362,588
R01 · FY2010 · EY · contact PI
Autophagy: A critical factor in RPE aging and AMD$359,736
R01 · FY2010 · EY · contact PI
Targeting gamma-secretase activation for anti-angiogenesis$383,257
R01 · FY2009 · EY · contact PI
Autophagy: A critical factor in RPE aging and AMD$377,101
R01 · FY2009 · EY · contact PI
Targeting gamma-secretase activation for anti-angiogenesis$366,250
R01 · FY2009 · EY · contact PI
Targeting gamma-secretase activation for anti-angiogenesis$358,925
R01 · FY2008 · EY · contact PI
Targeting gamma-secretase activation for anti-angiogenesis$313,520
R01 · FY2007 · EY · contact PI
Targeting gamma-secretase activation for anti-angiogenesis$72,986
R01 · FY2007 · EY · contact PI